SMAM
JAZZ icon

Sugar Maple Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Sugar Maple Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,500
Closed -$301K – 60
2024
Q1 		$301K Buy
+2,500
New +$306K 0.29% 43

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Sugar Maple Asset Management's JAZZ Position: Q2 2024 in Review

Sugar Maple Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 2,500 shares — an estimated $301K sold.

Sugar Maple Asset Management first reported a position in JAZZ in Q1 2024 and held it in 1 quarter. The position peaked at $301K in Q1 2024. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

  • Sugar Maple Asset Management reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Sugar Maple Asset Management sold 2,500 Jazz Pharmaceuticals shares in Q2 2024, an estimated $301K.
  • Sugar Maple Asset Management first reported a position in Jazz Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Sugar Maple Asset Management's Jazz Pharmaceuticals position peaked at $301K in Q1 2024.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Sugar Maple Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.